Lipocine is trading at $1.60, down 5.03%, amid broader technology-share pressure, though a direct link is unconfirmed. - Hotter-than-expected inflation revived concerns about higher-for-longer interest rates; Nasdaq futures were down 1.1% Thursday morning. - No new company-specific announcement explaining the decline was identified; Lipocine’s latest located company news was its October 7 Health Canada approval announcement.